›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Healthcare

Healthcare

CNS Therapeutics

Tue, 06/12/2012 - 10:25 -- admin

Founded by recognized leaders in intrathecal therapies, CNS Therapeutics developed and brought to market safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system. CNS was acquired by Covidien in 2012.

Xenon Pharmaceuticals

Mon, 06/11/2012 - 11:20 -- admin

Xenon is a clinical genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, Xenon identifies and validates new targets for drug development and converts that knowledge into innovative and differentiated medicines. Its programs focus on indications of important unmet medical needs, including pain, anemia, iron overload, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials. The company is headquartered in Burnaby, British Columbia.

USDS

Mon, 06/11/2012 - 11:17 -- admin

USDS independently evaluates medical laboratory diagnostic tests to validate quality, speed development, assure alignment with regulatory requirements, guide regulatory pathway strategy, and inform reimbursement decisions. The performance, intended use, and risk assessment of diagnostic tests are certified through the company’s DxSTANDARDS process, which uses standards and methods based on the consensus of regulatory, industry, and academic experts.

Trius Therapeutics

Mon, 06/11/2012 - 11:17 -- admin

Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company is addressing the need for novel therapeutics to treat multi-drug-resistant bacterial infections as they become more resistant to currently marketed drugs. Trius was acquired by Cubist in 2013.

Transcept Pharmaceuticals

Mon, 06/11/2012 - 11:15 -- admin

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The Transcept drug-delivery system enhances the absorption of drug active agents, reduces first-pass drug inactivation by the liver, and decreases the time required for the onset of drug action, potentially to a level approaching that of parenteral administration.

TESARO

Mon, 06/11/2012 - 11:15 -- admin

Tesaro (TSRO) is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.

Sera Prognostics

Mon, 06/11/2012 - 11:12 -- admin

Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.

ReVision Optics

Mon, 06/11/2012 - 11:09 -- admin

ReVision Optics develops custom optical solutions dedicated to vision correction. Its first product is the Vue+ inlay, a unique patented refractive surgery solution which improves near vision that has been lost by presbyopia, the eye's natural aging process. Vue+ is approved in Europe, has its CE mark, and ReVision is actively pursuing regulatory approvals and market opportunities worldwide.

RadioRx

Mon, 06/11/2012 - 11:07 -- admin

RadioRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.

Pages

Subscribe to RSS - Healthcare
Facebook Google+ Twitter Email LinkedIn Share